ÀÇ·á¹ýÀÎ ÀÌ¿øÀÇ·áÀç´Ü
EDTA tube
÷°¡Á¦ K2 EDTA
ÇØ´ç°Ë»ç CBC, ABO, Rh, ABO Subtyping, Diff Count, Eosinophil Count, ESR, DAT,Du test, Reti, Malaria, HbAIc, PB morphology
°Ëü·® 3mL
º¸°ü ¿ë±â: ½Ç¿Â, äÇ÷ ÈÄ ³ÃÀå
Âü°í»çÇ× Ã¤Ç÷ ÈÄ Ç×ÀÀ°íÁ¦¿Í ÃæºÐÈ÷ È¥ÇÕ

´Ý±â

°Ë»çÇ׸ñ

ÃֽŠ°Ë»çÇ׸ñ°ú °Ë»çÆгÎÀ» È®ÀÎÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.

°Ë»çÇ׸ñ Á¶È¸

TPMT Major polymorphism

Àμâ
°Ë»çºÐ¾ß
ºÐÀÚÀ¯Àü°Ë»ç
: À¯Àü¼º(germline) À¯ÀüÀÚ °Ë»ç
°Ë»çÄÚµå
H00791
ºÐ·ù¹øÈ£
³ª580´Ù(1)
º¸ÇèÄÚµå
C5806356Z
°Ë»ç¹æ¹ý
Sequencing
°Ë»çÀÏ
¿ù-±Ý
¼Ò¿äÀÏ
7ÀÏ

*Åä, ÀÏ, °øÈÞÀÏ ¹ÌÆ÷ÇÔ
°Ë»ç¼ö°¡
£Ü183,290

*Áú°¡»ê·á¸¦ Æ÷ÇÔÇÏÁö ¾Ê½À´Ï´Ù.
°ËüÁ¾·ù

EDTA tube

°Ëü·® 4mL
°Ëüº¸°ü ³ÃÀå
°Ëü¾ÈÁ¤¼º ½Ç¿Â: 1ÀÏ
³ÃÀå: 7ÀÏ
Âü°íÄ¡
ÀÓ»óÀûÀÇÀÇ Thiopurine methyltransferase (TPMT)´Â azathioprine, 6-mercaptopurine, thioguanineÀÇ s-methylation¿¡ °ü¿©ÇÏ´Â È¿¼Ò·Î¼­, ÀÌ È¿¼Ò¸¦ »ý¼ºÇÏ´Â TPMT À¯ÀüÀÚÀÇ À¯ÀüÇü(genotype)¿¡ µû¶ó È¿¼ÒÈ°¼ºµµ°¡ °áÁ¤µÈ´Ù. TPMT È¿¼ÒÀÇ ´ë»ç´ÉÀÌ ÀúÇϵǴ º¯ÀÌÇüÀ» °¡Áø ȯÀÚ¿¡¼­ »ó±â ¾àÁ¦ Åõ¾à ½Ã myelosuppression, leukopenia µî ¾àÁ¦ µ¶¼ºÀÌ ÈçÇϹǷΠ°¨·® Åõ¾àÀÌ ÇÊ¿äÇÏ´Ù. ÀÌ °Ë»ç´Â Çѱ¹Àο¡¼­ º¸°íµÈ º¯ÀÌ À¯ÀüÇüÀÎ *3C, *6, *16, *32 ¹× *38À» °ËÃâÇÒ ¼ö ÀÖÀ¸¸ç, °Ë»ç ´ë»ó ¿µ¿ª¿¡ º¯ÀÌ°¡ ¾øÀ¸¸é *1/*1·Î ÆÇÁ¤ÇÑ´Ù. Çѱ¹ÀÎÀÇ TPMT*1, *3C, *6 allele ºóµµ´Â °¢°¢ 98.2%, 1.4%, 0.2%ÀÌ´Ù.

-°Ë»ç¹üÀ§: Exon 4, 6, 7, and 9
-°ËÃâ°¡´É À¯ÀüÇü: Çѱ¹ÀÎ º¯ÀÌÇü 5Á¾À» Æ÷ÇÔÇÑ 28Á¾(È°¼ºÀúÇÏ º¯ÀÌÇü 8Á¾ Æ÷ÇÔ)
-Coverage: Çѱ¹ÀÎÀÇ ~100%, Àü¼¼°èÀÎÀÇ 99.9%
ÁÖÀÇ»çÇ× È¯ÀÚ º»ÀÎÀÌ ¿Ü±¹ÀÎÀ̰ųª Á÷°è Á¸¼ÓÀÌ ¿Ü±¹ÀÎÀÎ °æ¿ì º°µµ ¹®ÀÇ ÇÊ¿ä
Çʼö¼­·ù À¯ÀüÀڰ˻絿ÀǼ­ºÐÀÚÀ¯Àü°Ë»çÀÇ·Ú¼­
ÃֽŰø¹®
±Þ¿©±âÁØ TPMT Gene °Ë»çÀÇ ±Þ¿©±âÁØ [°í½Ã Á¦2020-135È£]

1. ³ª580³ª(1) À¯Àü¼º À¯ÀüÀÚ°Ë»ç-ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ-È®Àå-ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ-±³Àâ¹ÝÀÀ [TPMT Gene], ³ª580´Ù(1) À¯Àü¼º À¯ÀüÀÚ°Ë»ç-¿°±â¼­¿­ºÐ¼®-¿°±â¼­¿­¹ÝÀÀ 
Sequencing Reaction 10ȸ ÀÌÇÏ [TPMT Gene], ³ª580´Ù(2)À¯Àü¼º À¯ÀüÀÚ°Ë»ç-¿°±â¼­¿­ºÐ¼®-¿°±â¼­¿­¹ÝÀÀ Sequencing Reaction 10ȸ ÃÊ°ú 20ȸ ÀÌÇÏ [TPMT Gene]Àº Thiopurine Á¦Á¦ Åõ¾à Áß ½ÉÇÑ °ñ¼ö¾ïÁ¦ µî ¾àÁ¦ ºÎÀÛ¿ëÀÌ ÀǽɵǾî À¯Àüº¯À̸¦ È®ÀÎÇϱâ À§ÇØ ½Ç½ÃÇÑ °æ¿ì ¿ä¾ç±Þ¿©¸¦ ÀÎÁ¤ÇÔ.

2. Thiopurine Á¦Á¦ Åõ¾à °èȹÀÌ Àִ ȯÀÚ Áß »ó±â 1. ÀÌ¿Ü ½Ç½ÃÇϴ °æ¿ì¿¡´Â ¡¸¼±º°±Þ¿© ÁöÁ¤ ¹× ½Ç½Ã µî¿¡ °üÇÑ ±âÁØ¡¹¿¡ µû¶ó º»Àκδã·üÀ» 80%·Î Àû¿ëÇÔ.

(2020.7.1. ½ÃÇà)